This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Researchers To Present Clinical Trial Data With Soliris® (eculizumab) Treatment In Both Approved Indications – PNH And AHUS – At ASH Annual Meeting

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that researchers will present data from clinical studies of Soliris ® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening and ultra-rare diseases caused by chronic uncontrolled complement activation, at the 55th Annual Meeting of the American Society of Hematology (ASH). Soliris is the first and only approved treatment for PNH and aHUS. Abstracts summarizing these data are published on the ASH website and can be accessed using the links below. The ASH annual meeting will be held December 7-10, 2013, at the Ernest N. Morial Convention Center in New Orleans.

Soliris was first approved in 2007 and is now approved in nearly 50 countries as a treatment for patients with PNH, a debilitating, ultra-rare and life-threatening blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells). Soliris is also approved in the United States (2011), European Union (2011), Japan (2013) and other countries as a treatment for patients with aHUS, a genetic, chronic and ultra-rare disease associated with vital organ failure and premature death.

Soliris and PNH

The following abstract will be presented in a poster session on Saturday, December 7, 2013 from 5:30 – 7:30 p.m., Central Standard Time (CST):

Abstract 1241: “Baseline Assessment of GPI-anchored Protein Deficient Blood Cells in Patients with Bone Marrow Failure (The OPTIMA study),” Obara, et al.

Accessible at: https://ash.confex.com/ash/2013/webprogram/Paper63472.html

The following abstracts will be presented in a poster session on Monday, December 9, 2013 from 6:00 – 8:00 p.m., Central Standard Time (CST):

Abstract 3715: “Periodic Evaluation of the Clone Size is Mandatory in PNH: A Study of the Spanish Cohort of the International PNH Registry,” Villegas, et al.

Accessible at: https://ash.confex.com/ash/2013/webprogram/Paper60116.html

Abstract 3720: “Clinical Signs and Symptoms in Non-transfused Patients with Paroxysmal Nocturnal Hemoglobinuria from a Korean Prospective PNH Registry,” Lee, et al.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs